Semaglutide is the most evidence-grounded peptide on this site. The STEP, SUSTAIN, and SELECT phase 3 programmes enrolled over 25,000 participants and form the basis for FDA-approved indications in type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). Unlike every other peptide we cover, its efficacy has been demonstrated in randomized controlled trials against placebo.
Strong human RCT evidence across STEP, SUSTAIN, and SELECT trials. Average ~15% body-weight loss in STEP 1; 20% reduction in major adverse cardiovascular events in SELECT. Three FDA-approved formulations.
Significant gastrointestinal side effects, black-box thyroid C-cell warning, supply shortages, and widespread gray-market compounding. Cost barriers (>$1,000/month without coverage) drive counterfeit and compounded risk.
Semaglutide has become the most prescribed peptide in pharmaceutical history. Ozempic alone generated more than $13 billion in 2024 sales. Wegovy established weight management as a legitimate FDA-approved indication. The cultural conversation around GLP-1 agonists extends from celebrity endorsements to concerns about supply and compounding.
This page is a map of what the randomized controlled trials actually show — what semaglutide does in humans, what it does not do, and where the evidence ends. Where the four other peptide pages on this site describe compounds with no confirmed human efficacy, semaglutide is in a different evidentiary category entirely.
What Is Semaglutide?
Semaglutide is a synthetic analog of the endogenous incretin hormone GLP-1 (glucagon-like peptide-1). It's a 30-amino-acid peptide with a modified fatty-acid side chain that extends half-life to roughly one week, enabling once-weekly subcutaneous dosing. The molecule was developed by Novo Nordisk and approved by the FDA in three distinct formulations.
The three approved formulations are: Ozempic (subcutaneous, type 2 diabetes, approved 2017); Wegovy (subcutaneous, chronic weight management at BMI ≥27 with comorbidity or BMI ≥30, approved 2021); and Rybelsus (oral tablet, type 2 diabetes, approved 2019). Each formulation targets a clinically-distinct population with separate dosing and trial evidence.
The distinction that matters
It's important to separate semaglutide's three different regulatory contexts:
- Type 2 diabetes (T2D) — Ozempic & Rybelsus — the first approved indication. Glycemic control (HbA1c reduction) and cardiovascular risk reduction are the primary endpoints supported by SUSTAIN-6 and subsequent trials.
- Chronic weight management — Wegovy — approved 2021 based on STEP 1–4 trials showing average weight loss of ~15% body weight at 2.4 mg weekly dosing. A separate indication, not a dose extension of Ozempic.
- Compounded "research" / gray-market semaglutide — the category that emerged during the 2023–2024 supply shortage. Compounded pharmacy versions operate in a regulatory gray zone, and are not FDA-reviewed for safety or efficacy.
The online conversation routinely conflates these contexts. Discussions of "semaglutide for weight loss" mix approved Wegovy data with off-label Ozempic use and compounded gray-market versions — three very different evidence and regulatory situations.
Mechanism of Action
Semaglutide's mechanism is well-characterized and clinically validated. The peptide acts as a long-acting GLP-1 receptor agonist:
- Binds the GLP-1 receptor on pancreatic beta cells, increasing glucose-dependent insulin secretion. The glucose-dependence limits hypoglycemia risk relative to sulfonylureas.
- Suppresses glucagon release from pancreatic alpha cells in the postprandial state, reducing hepatic glucose output during meals.
- Slows gastric emptying, blunting post-meal glucose excursions and contributing to early satiety — a key driver of the weight-loss effect.
- Acts on hypothalamic appetite centers, reducing hunger signaling and food-reward response. Functional MRI studies show altered activity in reward-processing regions during food cues.
- Cardiovascular mechanisms: improves endothelial function, reduces blood pressure, slows atherosclerotic progression — proposed mediators of the SELECT trial's 20% MACE reduction.
These mechanisms are not marketing claims — they're documented in the peer-reviewed pharmacology literature. Drucker 2018 (Cell Metab) reviewed the GLP-1 receptor signaling cascade. Nauck 2021 (Diabetologia) characterized the incretin effect. Marso 2016 (NEJM, SUSTAIN-6) and Lincoff 2023 (NEJM, SELECT) demonstrated cardiovascular outcomes in humans. The mechanism-to-outcome chain is supported by randomized controlled trial data — a category of evidence the other peptides on this site cannot claim.
Mechanism vs. efficacy, semaglutide-version: Where TB-500 and BPC-157 have plausible mechanisms without confirmed human efficacy, semaglutide is the inverse. The mechanism is plausible and the outcomes are RCT-confirmed — with the corollary that the documented adverse-event profile (GI side effects, thyroid C-cell concern, pancreatitis risk) is also real and dose-related.
The Evidence Landscape
| Indication | Evidence Level | Best Study / Citation |
|---|---|---|
| Wound healing (skin, soft tissue) | Strong animal | Philp 2006, Exp Cell Res — rodent wound models; consistent replication across labs. PMID: 16841073 |
| Angiogenesis / blood vessel formation | Moderate animal | Malinda 1999, Int J Mol Med — in vitro and mouse models. PMID: 10496477 |
| Cardioprotection (post-MI) | Moderate animal | Mouse MI model, functional improvement observed. PMID: 14630500 |
| Corneal wound healing (orphan drug basis) | Exploratory human | Early human tissue studies; no completed Phase III trial. Basis for 2018 orphan designation. |
| Tendon / ligament repair | Not established | No human data. Animal models limited; no independent replication of tendon-specific effects. |
| Systemic anti-inflammatory / anti-aging | Not established | No published human data. Extrapolated from animal inflammation models. |
The animal literature: substantial but not conclusive
The animal literature for TB-500 is genuine and not dismissible. The wound healing data — particularly for epithelial and dermal tissue — shows consistent results across multiple independent research groups. The G-actin binding mechanism is well-characterized, and cell migration effects are replicable in vitro.
The cardioprotection data is similarly interesting: a compound that meaningfully reduces infarct size in animal models of MI would be pharmacologically significant. The translation to human cardiovascular applications, however, has not occurred.
Where the animal literature gets thinner is musculoskeletal applications. Tendon and ligament biology in rodents differs from humans in healing rate, biomechanical loading, and immune environment. An effect observed in a rat Achilles tendon repair model doesn't automatically translate to a human weightlifter with a partial rotator cuff tear.
The Vendor Reality
This is the part that most TB-500 discussions omit, and it's significant enough to address directly.
TB-500 sold online — through peptide vendors, gray-market pharmacies, and international resellers — is not subject to the same quality controls as an FDA-approved drug. The compound may be:
- Pure and accurately dosed — or contaminated with endotoxins, particulate matter, or incorrect peptides
- Correctly handled and stored — or degraded by improper shipping and handling
- Actually TB-500 — or a different peptide mislabeled, since peptide quality varies enormously between manufacturers
The compounding pharmacy route (503A/503B) offers some quality assurances — these pharmacies are regulated and required to meet USP standards for purity and potency. Gray-market peptide vendors operate with no equivalent oversight. Independent lab testing (via services like Corejo or Confarma) is the only way to verify what you're actually receiving.
What to verify before buying TB-500: Ask for a Certificate of Analysis (COA) from an independent lab. It should show identity confirmation (mass spectrometry or HPLC), purity (typically >95%), and endotoxin testing. If a vendor can't or won't provide this, don't buy from them.
Regulatory Status in 2026
FDA status
TB-500 is not an FDA-approved drug. It has no approved indication in the United States. The 2018 orphan drug designation covers a specific corneal wound healing use — it does not confer approval, and no product has completed the clinical trials required to convert that designation into market authorization.
WADA / athletic prohibition
TB-500 (Thymosin Beta-4) is explicitly listed under WADA's S0 category — substances prohibited at all times with no recognized therapeutic use. This is the same category as BPC-157. Athletes subject to WADA testing (professional, Olympic, collegiate in most countries) face a positive test result if TB-500 is detected, regardless of sourcing, dose, or rationale for use.
Compounding gray zone
TB-500 is frequently compounded by pharmacies operating under 503A or 503B frameworks, or sourced from gray-market peptide vendors. The July 2026 FDA compounding reclassification meeting may affect TB-500's status — the FDA has signaled that peptides with no suitable monograph and no completed clinical pathway may face restrictions in the compounding context.
What this means practically: TB-500 purchased outside FDA-approved channels is an unregulated compound. The quality, purity, and dosing accuracy of any product you acquire is unknowable without independent lab testing. The regulatory gray zone means there is no manufacturer accountability if the product is mislabeled, degraded, or contaminated.
TB-500's regulatory framing changes month to month — orphan-designation motion, compounding eligibility, WADA list updates, and DOJ enforcement all matter. The dated Regulatory Updates Log tracks the primary-source documents as they're published.
View TB-500 regulatory entries →TB-500 vs. BPC-157
The two peptides are frequently discussed together — both are in the S0 WADA prohibition category, both have extensive animal literature and zero human RCTs, and both are discussed online as recovery compounds. The comparison is worth making carefully.
Mechanistic difference: BPC-157 is a pentadecapeptide (15 amino acids) derived from a GI protein, with proposed angiogenic and growth-factor-modulating mechanisms. TB-500 is a 43-amino-acid endogenous peptide with G-actin binding as its primary characterized mechanism. They are fundamentally different compounds.
Evidence overlap: Both have strong animal wound healing data. BPC-157 has a more extensive musculoskeletal injury model literature (tendon, ligament, bone); TB-500 has stronger corneal/epithelial wound healing data and more cardiac model data.
Human evidence: Neither has published human RCTs for musculoskeletal applications. Both are in the same regulatory and evidence position — animal promise, human absence.
Athletic prohibition: Both are S0 prohibited at all times under WADA rules.
The key distinction: neither compound should be discussed as if the animal data constitutes evidence of human efficacy. The online communities that discuss TB-500 and BPC-157 as if the science is settled are extrapolating well beyond what the evidence supports.
The Honest Verdict
Here's the straightforward assessment:
TB-500 has consistent wound healing effects in animal models. The G-actin binding mechanism is real, the cell migration effects are replicable, and the dermal wound healing data is not disputed. This is genuine pharmacology.
The mechanism is biologically plausible for musculoskeletal repair. If cell migration and actin reorganization genuinely accelerate tissue healing, tendon and ligament applications would theoretically benefit. The leap from plausible to proven requires human data that doesn't exist yet.
No human data supports systemic injectable TB-500 for any musculoskeletal indication. The tendon and ligament repair claims circulating online are extrapolations from animal models — not clinical evidence. No Phase I/II safety or efficacy trial has been published.
The July 2026 FDA compounding reclassification may restrict access. TB-500 is in the category of peptides the FDA has flagged for potential compounding restrictions. If moved to Category 1, access through 503A compounding pharmacies may be affected. The regulatory landscape is active and may change within months.
TB-500 is a research chemical with an interesting mechanism and genuine animal data — not a proven therapy for human injuries. The compound is worth investigating in research contexts. It is not something to use with confidence based on forum testimonials and animal studies.
If you're considering TB-500, the minimum due diligence is: understand what you're actually buying (request a COA), know the WADA implications if you're an athlete, and talk to a physician familiar with peptide therapy who is not also selling the compound to you.
References
- Goldman RD, et al. "Thymosin beta-4 and G-actin: signaling in cell migration." J Cell Biol. 1989. PMID: 2642584
- Malinda KM, et al. "Thymosin beta-4 accelerates wound healing." Int J Mol Med. 1999. PMID: 10496477
- Philp D, et al. "Thymosin beta-4 and wound healing." Exp Cell Res. 2006. PMID: 16841073
- Saudek F, et al. "Thymosin beta-4 and cardiac repair." J Mol Cell Cardiol. (Mouse MI study.) PMID: 14630500
- FDA Orphan Drug Designations database — Thymosin Beta-4, 2018.
- WADA Prohibited List 2026 — S0 category, Thymosin Beta-4.
- STAT News. "The gray market for unapproved peptide therapies." 2025.
- Nature. "The peptide problem: why consumers are buying unregulated compounds." 2025.
Questions to Ask Before You Buy Anything
Our free Peptide Therapy Decision Checklist walks you through the questions a qualified physician would ask — including what to verify about sourcing, quality, and regulatory status before you buy anything.
Download the Free Checklist Get the Long-Form Guide — $37